Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 8, 2017

Croda Completes Global EXCiPACT Accreditation

The company is the first multi-site excipient supplier to achieve accreditation across production facilities.

Croda announced that all its global excipient manufacturing sites have completed EXCiPACT audit requirements and have been certified according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. The certifications are given after manufacturing processes, quality systems, quality management, and storage and distribution facilities are inspected during audits.

"This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda's compliance to the demanding standards of the pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards," said Dave Cherry, managing director of Croda’s Health Care business, in a press statement.

Source: Croda 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.